Genomic risk was also compared with other individual clinical parameters, including grade, size, node implication, percentage of Ki67 cells, ER and PR expression, and HER2 overexpression to assess whether the use of genomic risk profiling would improve the positive predictive value (PPV) for breast cancer prognosis. This evidence concerns the gene ERBB2 and breast carcinoma.